Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00766155
First received: October 2, 2008
Last updated: September 28, 2011
Last verified: September 2011
  Purpose

RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy that uses a 3-dimensional image of the tumor to help focus thin beams of radiation directly on the tumor may kill more tumor cells and have fewer side effects. Giving chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether capecitabine is more effective with or without oxaliplatin in treating patients with rectal cancer.

PURPOSE: This randomized phase III trial is studying giving chemotherapy together with radiation therapy before surgery followed by capecitabine with or without oxaliplatin to see how well it works in treating patients with locally advanced rectal cancer.


Condition Intervention Phase
Colorectal Cancer
Drug: capecitabine
Drug: oxaliplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Preoperative Chemoradiotherapy and Postoperative Chemotherapy With Capecitabine and Oxaplatin vs.Capecitabine Alone in Locally Advanced Rectal Cancer (PETACC-6)

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Disease-free survival [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival within at least the first 5 years after treatment [ Designated as safety issue: No ]
  • Loco-regional failure, defined as local or regional recurrence, inoperable disease, or R1 or R2 resection [ Designated as safety issue: No ]
  • Distant failure (i.e., distant metastasis) [ Designated as safety issue: No ]
  • Pathological down-stage (ypT0, 2N0) rate [ Designated as safety issue: No ]
  • Pathological complete remission (ypT0N0) rate [ Designated as safety issue: No ]
  • Tumor regression grade [ Designated as safety issue: No ]
  • Histopathological R0 resection rate [ Designated as safety issue: No ]
  • Sphincter preservation rate [ Designated as safety issue: No ]
  • Preoperative complication rate [ Designated as safety issue: No ]
  • Toxicity according to CTCAE v.3.0 weekly during treatment, at 4-8 weeks after surgery, at therapy completion, and every 6 months for 5 years after therapy completion [ Designated as safety issue: Yes ]

Estimated Enrollment: 1090
Study Start Date: August 2008
Arms Assigned Interventions
Active Comparator: Arm I
Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: capecitabine
Given orally
Experimental: Arm II
Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: capecitabine
Given orally
Drug: oxaliplatin
Given IV

Detailed Description:

OBJECTIVES:

Primary

  • Investigate whether the addition of oxaliplatin to neoadjuvant chemoradiotherapy and adjuvant chemotherapy comprising capecitabine improves disease-free survival in patients with locally advanced rectal cancer.

Secondary

  • Compare the overall survival of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and adjuvant chemotherapy comprising capecitabine with versus without oxaliplatin.
  • Determine the loco-regional failure and distant failure of patients treated with these regimens.
  • Determine the pathological down-staging (ypT0-2N0) of patients treated with these regimens.
  • Determine the pathological complete remission (yp T0N0) rate of patients treated with these regimens.
  • Determine the tumor progression grade and histopathological R0 resection of patients treated with these regimens.
  • Determine the sphincter preservation rate of patients treated with these regimens.
  • Determine the perioperative complication rate of these regimens in these patients.
  • Determine the toxicity of these regimens in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to treating center, clinical T category (T1-3 vs T4), clinical nodal status (Nx vs NO vs N1-2), distance from the tumor to the anal verge (≤ 5 cm vs > 5 cm) and method of locoregional staging (EUS+MRI vs EUS+CTscan vs MRI alone). Patients are randomized to 1 of 2 treatment arms.

  • Arm I (control):

    • Neoadjuvant therapy: Patients receive oral capecitabine twice daily on days 1-35. Patients also undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33 followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38.
    • Adjuvant therapy: Beginning 4-8 weeks after surgery, patients receive oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II (investigational):

    • Neoadjuvant therapy: Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38.
    • Adjuvant therapy: Beginning 4-8 weeks after surgery, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed every 3 months for 3 years, and then every 6 months for 2 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the rectum

    • Tumor ≤ 12 cm from the anal verge
    • Stage T3-4 or any node-positive disease
  • No evidence of metastatic disease (confirmed by negative CT scan of the chest and abdomen)
  • Resectable disease or expected to become resectable after preoperative chemoradiation
  • May only be randomized once in this trial

PATIENT CHARACTERISTICS:

  • WHO/ECOG performance status 0-2
  • Hemoglobin ≥ 10.0 g/dL (transfusion allowed to achieve or maintain levels)
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • ALT and AST ≤ 2.5 times upper level of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Total bilirubin ≤ 1.5 times ULN
  • Creatinine clearance > 50 mL/min
  • Creatinine ≤ 1.5 times ULN
  • Able to swallow tablets
  • No prior or concurrent malignancies within the past 5 years except for adequately treated cone-biopsied carcinoma in situ of the cervix or basal cell carcinoma of the skin
  • No clinically significant (i.e., active) cardiac disease, including any of the following:

    • Congestive heart failure
    • Symptomatic coronary artery disease
    • Cardiac arrhythmia
  • No myocardial infarction within the past 12 months
  • No known significant impairment of intestinal resorption (e.g., chronic diarrhea, inflammatory bowel disease)
  • No pre-existing conditions that would preclude chemoradiotherapy or radiotherapy (i.e., fistulas, severe ulcerative colitis [particularly patients currently taking sulfasalazine], Crohn's disease, or prior adhesions)
  • No peripheral neuropathy ≥ grade 2 by CTCAE v3.0
  • No serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease
  • No history of uncontrolled seizures, central nervous system disorders or psychiatric disability that, in the opinion of the principal investigator, is clinically significant and would preclude giving informed consent or interfere with compliance with oral drug administration
  • No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Not pregnant or nursing
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

  • No prior cytotoxic chemotherapy or radiation therapy for rectal cancer
  • No prior radiation therapy to the pelvis
  • No prior or concurrent investigational drug, agent, or procedure
  • More than 4 weeks since prior participation in the active or follow-up period of another investigational protocol
  • No known allergy or any other adverse reaction to any of the study drugs or to any related compound
  • No known dihydropyrimidine dehydrogenase deficiency
  • No organ allograft requiring immunosuppressive therapy
  • No concurrent sorivudine or chemically related analogues (e.g., brivudine)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00766155

Locations
Germany
Universitaetsklinikum Halle
Halle, Germany, D-06097
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Investigators
Principal Investigator: Hans-Joachim Schmoll, MD, PhD Martin-Luther-Universität Halle-Wittenberg
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00766155     History of Changes
Other Study ID Numbers: CDR0000614916, EORTC-40054, EU-20880, PETACC-6, EORTC-22062, ROCHE-EORTC-40054, EUDRACT-2006-006532-21
Study First Received: October 2, 2008
Last Updated: September 28, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage II rectal cancer
stage III rectal cancer
adenocarcinoma of the rectum

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Capecitabine
Fluorouracil
Oxaliplatin
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014